Samsung Biologics said Wednesday that it has launched S-CHOice, its proprietary cell line technology. A cell line is a cell that multiplies in vitro to make a desired antibody drug.

"S-CHOice multiplies faster than other cell lines and survives for a longer period," the company said. "It also shows improved titers up to two-fold from industry average, reaching above 7 g/L for standard monoclonal antibodies, and enhanced cell viability of more than 90 percent at day 21 in a fed-batch study."

Besides, S-CHOice has a speedy cell division of 18-20 hours. Together with the company's Berkeley Lights Beacon technology, Samsung Biologics expects to reduce development timeline by a month from the industry average of four to five months, the company added.

The company plans to provide attractive payment terms for clients choosing to use this cell line technology for their future development.

"Through S-CHOice, we will be able to provide services with overwhelming speed and quality compared to other existing global biopharmaceutical industries," Samsung Biologics CEO Kim Tae-han said. “The company expects to increase customer satisfaction based on S-CHOice's strong performance, helping to meet global drug supply demands and increasing the success rate of new drug development."